Get started
Author

Arturo Ciccullo

Observed names: A Ciccullo, A. Ciccullo, Ciccullo A, Ciccullo Arturo, Ciccullo, Arturo
Observed institutions: Università Cattolica del Sacro Cuore, University of L'Aquila, Agostino Gemelli University Polyclinic, San Salvatore Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Regione Molise
ORCID: 0000-0001-5941-883X
Observed ORCID: 0000-0001-5941-883X
OpenAlex ID: A5016247442
Post-COVID-19 global health strategies: the need for an interdisciplinary approach
2020 · Gemelli Against COVID-19 Post-Acute Care Study Group, F. Landi, et al. · Aging Clinical and Experimental Research · 279
PDF
Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection
2020 · Simona Di Giambenedetto, Arturo Ciccullo, et al. · Journal of Medical Virology · 153
PDF
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
2020 · Francesco Perrone, Maria Carmela Piccirillo, et al. · Journal of Translational Medicine · 144
PDF
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line
2020 · Arturo Ciccullo, Alberto Borghetti, et al. · International Journal of Antimicrobial Agents · 143
PDF
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study
2021 · Augusto Di Castelnuovo, Simona Costanzo, et al. · Thrombosis and Haemostasis · 123
PDF
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
2020 · Augusto Di Castelnuovo, Simona Costanzo, et al. · European Journal of Internal Medicine · 110
PDF
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
2018 · Roberta Gagliardini, Arturo Ciccullo, et al. · Open Forum Infectious Diseases · 65
PDF
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients
2019 · Gianmaria Baldin, Arturo Ciccullo, et al. · International Journal of Antimicrobial Agents · 57
PDF
COVID-19 and intestinal inflammation: Role of fecal calprotectin
2020 · Veronica Ojetti, Angela Saviano, et al. · Digestive and Liver Disease · 55
PDF
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry
2020 · Laura Galli, Maria Rita Parisi, et al. · Open Forum Infectious Diseases · 53
PDF
RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
2020 · Augusto Di Castelnuovo, Simona Costanzo, et al. · Vascular Pharmacology · 46
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV ‐1 replication
2018 · A Borghetti, G Baldin, et al. · HIV Medicine · 46
Malnutrition in COVID-19 survivors: prevalence and risk factors
2023 · Matteo Tosato, Riccardo Calvani, et al. · Aging Clinical and Experimental Research · 37
PDF
A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected Patients
2018 · Arturo Ciccullo, Gianmaria Baldin, et al. · Antiviral Therapy · 36
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
2020 · A. Cingolani, A. M. Tummolo, et al. · Infection · 35
PDF
Residual respiratory impairment after COVID-19 pneumonia
2021 · Francesco Lombardi, Angelo Calabrese, et al. · BMC Pulmonary Medicine · 34
PDF
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding
2021 · Arturo Ciccullo, Vanni Borghi, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 33
PDF
Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort
2021 · Massimiliano Fabbiani, Barbara Rossetti, et al. · HIV Medicine · 33
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study
2019 · Barbara Rossetti, Gianmaria Baldin, et al. · Antiviral Research · 32
PDF
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
2019 · Alberto Borghetti, Francesca Lombardi, et al. · BMC Infectious Diseases · 32
PDF
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice
2019 · Gianmaria Baldin, Arturo Ciccullo, et al. · Journal of Antimicrobial Chemotherapy · 29
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
2021 · Augusto Di Castelnuovo, Simona Costanzo, et al. · Frontiers in Medicine · 27
PDF
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy
2020 · Massimiliano Fabbiani, Alberto Borghetti, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 22
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Table 1.
2016 · A. Borghetti, G. Baldin, et al. · Journal of Antimicrobial Chemotherapy · 22
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate ( TDF ) or elvitegravir/cobicistat/emtricitabine/ TDF in virologically suppressed HIV ‐infected patients in clinical practice: results from a multicentre, observational study
2018 · G Baldin, A Ciccullo, et al. · HIV Medicine · 21
Works count: 139
Citation count: 2,349
H-index: 22
I10-index: 58
Year
Topic
Type